Athira Pharma Inc at Stifel CNS Days (Virtual) Transcript
Good afternoon, everyone. Thanks for joining. It's a pleasure to be joined by the Athira executive team here. Maybe Mark, it makes sense to just give a background. And I know you have some slides here, so feel free to walk through as many as you want, and then we can jump into some Q&A.
Yes. Okay, James. Sure. Let's just first do some introductions about who we have on this call. I'm Mark Litton, the CEO of Athira. I'm joined by our CMO, Hans Moebius; and I'm also joined by our CSO, Kevin Church. So many, many thanks for having us on this panel, fireside chat. Let me give you a little brief overview of who we are and then we can sort of jump into the questions.
So Athira is a late-stage clinical development company focused on repairing and protecting and restoring neuronal health. Our platform approach starts from enhancing a naturally occurring repair mechanism, the HGF system that our bodies use every day to protect, repair our nervous system. And there's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
